id	sid	tid	token	lemma	pos
qf85n873c5q	1	1	the	the	DET
qf85n873c5q	1	2	use	use	NOUN
qf85n873c5q	1	3	of	of	ADP
qf85n873c5q	1	4	anti	anti	ADJ
qf85n873c5q	1	5	-	-	ADJ
qf85n873c5q	1	6	androgen	androgen	ADJ
qf85n873c5q	1	7	therapy	therapy	NOUN
qf85n873c5q	1	8	for	for	ADP
qf85n873c5q	1	9	the	the	DET
qf85n873c5q	1	10	treatment	treatment	NOUN
qf85n873c5q	1	11	of	of	ADP
qf85n873c5q	1	12	invasive	invasive	ADJ
qf85n873c5q	1	13	and	and	CCONJ
qf85n873c5q	1	14	metastatic	metastatic	ADJ
qf85n873c5q	1	15	prostate	prostate	NOUN
qf85n873c5q	1	16	cancer	cancer	NOUN
qf85n873c5q	1	17	is	be	AUX
qf85n873c5q	1	18	common	common	ADJ
qf85n873c5q	1	19	practice	practice	NOUN
qf85n873c5q	1	20	.	.	PUNCT
qf85n873c5q	2	1	however	however	ADV
qf85n873c5q	2	2	,	,	PUNCT
qf85n873c5q	2	3	after	after	ADP
qf85n873c5q	2	4	an	an	DET
qf85n873c5q	2	5	initial	initial	ADJ
qf85n873c5q	2	6	response	response	NOUN
qf85n873c5q	2	7	,	,	PUNCT
qf85n873c5q	2	8	the	the	DET
qf85n873c5q	2	9	tumor	tumor	NOUN
qf85n873c5q	2	10	frequently	frequently	ADV
qf85n873c5q	2	11	progresses	progress	VERB
qf85n873c5q	2	12	to	to	PART
qf85n873c5q	2	13	'	'	PUNCT
qf85n873c5q	2	14	castrate	castrate	VERB
qf85n873c5q	2	15	resistant	resistant	ADJ
qf85n873c5q	2	16	prostate	prostate	NOUN
qf85n873c5q	2	17	cancer	cancer	NOUN
qf85n873c5q	2	18	'	'	PUNCT
qf85n873c5q	2	19	(	(	PUNCT
qf85n873c5q	2	20	crpc	crpc	PROPN
qf85n873c5q	2	21	)	)	PUNCT
qf85n873c5q	2	22	,	,	PUNCT
qf85n873c5q	2	23	and	and	CCONJ
qf85n873c5q	2	24	becomes	become	VERB
qf85n873c5q	2	25	very	very	ADV
qf85n873c5q	2	26	difficult	difficult	ADJ
qf85n873c5q	2	27	to	to	PART
qf85n873c5q	2	28	treat	treat	VERB
qf85n873c5q	2	29	.	.	PUNCT
qf85n873c5q	3	1	this	this	DET
qf85n873c5q	3	2	progression	progression	NOUN
qf85n873c5q	3	3	has	have	AUX
qf85n873c5q	3	4	been	be	AUX
qf85n873c5q	3	5	attributed	attribute	VERB
qf85n873c5q	3	6	to	to	ADP
qf85n873c5q	3	7	mutations	mutation	NOUN
qf85n873c5q	3	8	in	in	ADP
qf85n873c5q	3	9	the	the	DET
qf85n873c5q	3	10	androgen	androgen	NOUN
qf85n873c5q	3	11	receptor	receptor	NOUN
qf85n873c5q	3	12	.	.	PUNCT
qf85n873c5q	4	1	however	however	ADV
qf85n873c5q	4	2	,	,	PUNCT
qf85n873c5q	4	3	despite	despite	SCONJ
qf85n873c5q	4	4	its	its	PRON
qf85n873c5q	4	5	widespread	widespread	ADJ
qf85n873c5q	4	6	use	use	NOUN
qf85n873c5q	4	7	,	,	PUNCT
qf85n873c5q	4	8	the	the	DET
qf85n873c5q	4	9	mechanisms	mechanism	NOUN
qf85n873c5q	4	10	and	and	CCONJ
qf85n873c5q	4	11	effects	effect	NOUN
qf85n873c5q	4	12	of	of	ADP
qf85n873c5q	4	13	anti	anti	ADJ
qf85n873c5q	4	14	-	-	ADJ
qf85n873c5q	4	15	androgen	androgen	ADJ
qf85n873c5q	4	16	therapy	therapy	NOUN
qf85n873c5q	4	17	on	on	ADP
qf85n873c5q	4	18	prostate	prostate	NOUN
qf85n873c5q	4	19	cancer	cancer	NOUN
qf85n873c5q	4	20	cells	cell	NOUN
qf85n873c5q	4	21	are	be	AUX
qf85n873c5q	4	22	poorly	poorly	ADV
qf85n873c5q	4	23	understood	understand	VERB
qf85n873c5q	4	24	.	.	PUNCT
qf85n873c5q	5	1	utilizing	utilize	VERB
qf85n873c5q	5	2	flow	flow	NOUN
qf85n873c5q	5	3	cytometry	cytometry	NOUN
qf85n873c5q	5	4	,	,	PUNCT
qf85n873c5q	5	5	gene	gene	NOUN
qf85n873c5q	5	6	array	array	NOUN
qf85n873c5q	5	7	,	,	PUNCT
qf85n873c5q	5	8	qpcr	qpcr	PROPN
qf85n873c5q	5	9	and	and	CCONJ
qf85n873c5q	5	10	western	western	ADJ
qf85n873c5q	5	11	blotting	blotting	NOUN
qf85n873c5q	5	12	we	we	PRON
qf85n873c5q	5	13	have	have	AUX
qf85n873c5q	5	14	compared	compare	VERB
qf85n873c5q	5	15	the	the	DET
qf85n873c5q	5	16	response	response	NOUN
qf85n873c5q	5	17	of	of	ADP
qf85n873c5q	5	18	two	two	NUM
qf85n873c5q	5	19	androgen	androgen	NOUN
qf85n873c5q	5	20	receptor	receptor	NOUN
qf85n873c5q	5	21	positive	positive	ADJ
qf85n873c5q	5	22	cell	cell	NOUN
qf85n873c5q	5	23	lines	line	NOUN
qf85n873c5q	5	24	lncap	lncap	PROPN
qf85n873c5q	5	25	(	(	PUNCT
qf85n873c5q	5	26	which	which	PRON
qf85n873c5q	5	27	harbors	harbor	VERB
qf85n873c5q	5	28	a	a	DET
qf85n873c5q	5	29	mutated	mutate	VERB
qf85n873c5q	5	30	androgen	androgen	NOUN
qf85n873c5q	5	31	receptor	receptor	NOUN
qf85n873c5q	5	32	and	and	CCONJ
qf85n873c5q	5	33	the	the	DET
qf85n873c5q	5	34	pc-346c	pc-346c	PROPN
qf85n873c5q	5	35	(	(	PUNCT
qf85n873c5q	5	36	which	which	PRON
qf85n873c5q	5	37	expresses	express	VERB
qf85n873c5q	5	38	the	the	DET
qf85n873c5q	5	39	wild	wild	ADJ
qf85n873c5q	5	40	type	type	NOUN
qf85n873c5q	5	41	receptor	receptor	NOUN
qf85n873c5q	5	42	)	)	PUNCT
qf85n873c5q	5	43	to	to	PART
qf85n873c5q	5	44	bicalutamide	bicalutamide	VERB
qf85n873c5q	5	45	,	,	PUNCT
qf85n873c5q	5	46	the	the	PRON
qf85n873c5q	5	47	most	most	ADV
qf85n873c5q	5	48	commonly	commonly	ADV
qf85n873c5q	5	49	used	use	VERB
qf85n873c5q	5	50	anti	anti	ADJ
qf85n873c5q	5	51	-	-	NOUN
qf85n873c5q	5	52	androgen	androgen	NOUN
qf85n873c5q	5	53	in	in	ADP
qf85n873c5q	5	54	the	the	DET
qf85n873c5q	5	55	clinic	clinic	NOUN
qf85n873c5q	5	56	.	.	PUNCT
qf85n873c5q	6	1	bicalutamide	bicalutamide	NOUN
qf85n873c5q	6	2	induces	induce	VERB
qf85n873c5q	6	3	dose	dose	VERB
qf85n873c5q	6	4	dependent	dependent	ADJ
qf85n873c5q	6	5	effects	effect	NOUN
qf85n873c5q	6	6	on	on	ADP
qf85n873c5q	6	7	cell	cell	NOUN
qf85n873c5q	6	8	cycle	cycle	NOUN
qf85n873c5q	6	9	and	and	CCONJ
qf85n873c5q	6	10	cell	cell	NOUN
qf85n873c5q	6	11	death	death	NOUN
qf85n873c5q	6	12	in	in	ADP
qf85n873c5q	6	13	both	both	DET
qf85n873c5q	6	14	cell	cell	NOUN
qf85n873c5q	6	15	lines	line	NOUN
qf85n873c5q	6	16	.	.	PUNCT
qf85n873c5q	7	1	whole	whole	ADJ
qf85n873c5q	7	2	genome	genome	NOUN
qf85n873c5q	7	3	expression	expression	NOUN
qf85n873c5q	7	4	profiling	profiling	NOUN
qf85n873c5q	7	5	indicates	indicate	VERB
qf85n873c5q	7	6	that	that	SCONJ
qf85n873c5q	7	7	bicalutamide	bicalutamide	NOUN
qf85n873c5q	7	8	exerts	exert	NOUN
qf85n873c5q	7	9	similar	similar	ADJ
qf85n873c5q	7	10	,	,	PUNCT
qf85n873c5q	7	11	but	but	CCONJ
qf85n873c5q	7	12	not	not	PART
qf85n873c5q	7	13	identical	identical	ADJ
qf85n873c5q	7	14	effects	effect	NOUN
qf85n873c5q	7	15	on	on	ADP
qf85n873c5q	7	16	the	the	DET
qf85n873c5q	7	17	two	two	NUM
qf85n873c5q	7	18	cell	cell	NOUN
qf85n873c5q	7	19	lines	line	NOUN
qf85n873c5q	7	20	,	,	PUNCT
qf85n873c5q	7	21	suggesting	suggest	VERB
qf85n873c5q	7	22	that	that	SCONJ
qf85n873c5q	7	23	the	the	DET
qf85n873c5q	7	24	transition	transition	NOUN
qf85n873c5q	7	25	to	to	ADP
qf85n873c5q	7	26	crpc	crpc	PROPN
qf85n873c5q	7	27	is	be	AUX
qf85n873c5q	7	28	not	not	PART
qf85n873c5q	7	29	due	due	ADJ
qf85n873c5q	7	30	to	to	ADP
qf85n873c5q	7	31	somatic	somatic	ADJ
qf85n873c5q	7	32	mutations	mutation	NOUN
qf85n873c5q	7	33	in	in	ADP
qf85n873c5q	7	34	response	response	NOUN
qf85n873c5q	7	35	to	to	ADP
qf85n873c5q	7	36	treatment	treatment	NOUN
qf85n873c5q	7	37	.	.	PUNCT
qf85n873c5q	8	1	however	however	ADV
qf85n873c5q	8	2	these	these	DET
qf85n873c5q	8	3	experiments	experiment	NOUN
qf85n873c5q	8	4	identified	identify	VERB
qf85n873c5q	8	5	a	a	DET
qf85n873c5q	8	6	distinct	distinct	ADJ
qf85n873c5q	8	7	threshold	threshold	NOUN
qf85n873c5q	8	8	response	response	NOUN
qf85n873c5q	8	9	to	to	PART
qf85n873c5q	8	10	bicalutamide	bicalutamide	VERB
qf85n873c5q	8	11	:	:	PUNCT
qf85n873c5q	8	12	at	at	ADP
qf85n873c5q	8	13	low	low	ADJ
qf85n873c5q	8	14	doses	dose	NOUN
qf85n873c5q	8	15	of	of	ADP
qf85n873c5q	8	16	bicalutamide	bicalutamide	NOUN
qf85n873c5q	8	17	both	both	DET
qf85n873c5q	8	18	cell	cell	NOUN
qf85n873c5q	8	19	lines	line	NOUN
qf85n873c5q	8	20	induce	induce	VERB
qf85n873c5q	8	21	cell	cell	NOUN
qf85n873c5q	8	22	cycle	cycle	NOUN
qf85n873c5q	8	23	arrest	arrest	NOUN
qf85n873c5q	8	24	but	but	CCONJ
qf85n873c5q	8	25	no	no	DET
qf85n873c5q	8	26	significant	significant	ADJ
qf85n873c5q	8	27	level	level	NOUN
qf85n873c5q	8	28	of	of	ADP
qf85n873c5q	8	29	cell	cell	NOUN
qf85n873c5q	8	30	death	death	NOUN
qf85n873c5q	8	31	,	,	PUNCT
qf85n873c5q	8	32	while	while	SCONJ
qf85n873c5q	8	33	at	at	ADP
qf85n873c5q	8	34	higher	high	ADJ
qf85n873c5q	8	35	doses	dose	NOUN
qf85n873c5q	8	36	both	both	DET
qf85n873c5q	8	37	cell	cell	NOUN
qf85n873c5q	8	38	lines	line	NOUN
qf85n873c5q	8	39	exhibit	exhibit	VERB
qf85n873c5q	8	40	extensive	extensive	ADJ
qf85n873c5q	8	41	cell	cell	NOUN
qf85n873c5q	8	42	death	death	NOUN
qf85n873c5q	8	43	.	.	PUNCT
qf85n873c5q	9	1	this	this	DET
qf85n873c5q	9	2	threshold	threshold	ADJ
qf85n873c5q	9	3	response	response	NOUN
qf85n873c5q	9	4	appears	appear	VERB
qf85n873c5q	9	5	to	to	PART
qf85n873c5q	9	6	involve	involve	VERB
qf85n873c5q	9	7	the	the	DET
qf85n873c5q	9	8	p53	p53	NOUN
qf85n873c5q	9	9	axis	axis	NOUN
qf85n873c5q	9	10	,	,	PUNCT
qf85n873c5q	9	11	since	since	SCONJ
qf85n873c5q	9	12	many	many	ADJ
qf85n873c5q	9	13	of	of	ADP
qf85n873c5q	9	14	the	the	DET
qf85n873c5q	9	15	affected	affected	ADJ
qf85n873c5q	9	16	genes	gene	NOUN
qf85n873c5q	9	17	are	be	AUX
qf85n873c5q	9	18	downstream	downstream	ADJ
qf85n873c5q	9	19	of	of	ADP
qf85n873c5q	9	20	this	this	DET
qf85n873c5q	9	21	central	central	ADJ
qf85n873c5q	9	22	mediator	mediator	NOUN
qf85n873c5q	9	23	of	of	ADP
qf85n873c5q	9	24	cellular	cellular	ADJ
qf85n873c5q	9	25	stress	stress	NOUN
qf85n873c5q	9	26	.	.	PUNCT
qf85n873c5q	10	1	the	the	DET
qf85n873c5q	10	2	overview	overview	NOUN
qf85n873c5q	10	3	of	of	ADP
qf85n873c5q	10	4	gene	gene	NOUN
qf85n873c5q	10	5	expression	expression	NOUN
qf85n873c5q	10	6	changes	change	NOUN
qf85n873c5q	10	7	and	and	CCONJ
qf85n873c5q	10	8	cellular	cellular	ADJ
qf85n873c5q	10	9	responses	response	NOUN
qf85n873c5q	10	10	to	to	ADP
qf85n873c5q	10	11	higher	high	ADJ
qf85n873c5q	10	12	concentrations	concentration	NOUN
qf85n873c5q	10	13	of	of	ADP
qf85n873c5q	10	14	bicalutamide	bicalutamide	NOUN
qf85n873c5q	10	15	indicates	indicate	VERB
qf85n873c5q	10	16	that	that	SCONJ
qf85n873c5q	10	17	increased	increase	VERB
qf85n873c5q	10	18	doses	dose	NOUN
qf85n873c5q	10	19	of	of	ADP
qf85n873c5q	10	20	the	the	DET
qf85n873c5q	10	21	anti	anti	ADJ
qf85n873c5q	10	22	-	-	NOUN
qf85n873c5q	10	23	androgen	androgen	NOUN
qf85n873c5q	10	24	may	may	AUX
qf85n873c5q	10	25	have	have	VERB
qf85n873c5q	10	26	clinical	clinical	ADJ
qf85n873c5q	10	27	benefits	benefit	NOUN
qf85n873c5q	10	28	.	.	PUNCT